Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
November 12 2019 - 8:30AM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today
announced it ranked in Deloitte’s Technology Fast 500™, a listing
of the 500 fastest-growing technology, media, telecommunications,
life sciences and energy tech companies in North America now in its
25th year. Ligand’s revenue grew 250% during the period upon which
this list is based.
“This is the third time Ligand has been included in the
Technology Fast 500, and we are very pleased once again to be
recognized by Deloitte for our rapid revenue growth,” said John
Higgins, Chief Executive Officer of Ligand. “The years covered by
this ranking were highly productive for Ligand and featured
significant growth in revenue and cash flow. Our success in this
period was driven by great business execution, strong performance
by partnered programs and prolific deal making. Deloitte
highlighted in their announcement that the winners are the
companies that push boundaries, help organizations become more
efficient and productive, and ultimately enable businesses to drive
growth and revenue. We are proud to be recognized among such an
accomplished class.”
“This year marks the 25th anniversary of Deloitte’s Technology
Fast 500, so we are especially pleased to announce and congratulate
the 2019 winners,” said Sandra Shirai, vice chairman, Deloitte LLP,
and U.S. technology, media and telecommunications leader. “It’s
always inspiring to see how the Fast 500 companies are transforming
business and the world in which we live and work.”
About Deloitte’s 2019 Technology Fast 500™
Now in its 25th year, Deloitte’s Technology Fast 500 provides a
ranking of the fastest-growing technology, media,
telecommunications, life sciences and energy tech companies — both
public and private — in North America. Technology Fast 500 award
winners are selected based on percentage fiscal year revenue growth
from 2015 to 2018.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000, and current-year operating
revenues of at least $5 million. Additionally, companies must be in
business for a minimum of four years and be headquartered within
North America.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or
acquiring technologies that help pharmaceutical companies discover
and develop medicines. Our business model creates value for
stockholders by providing a diversified portfolio of biotech and
pharmaceutical product revenue streams that are supported by an
efficient and low corporate cost structure. Our goal is to offer
investors an opportunity to participate in the promise of the
biotech industry in a profitable, diversified and lower-risk
business than a typical biotech company. Our business model is
based on doing what we do best: drug discovery, early-stage drug
development, product reformulation and partnering. We partner with
other pharmaceutical companies to leverage what they do best
(late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
OmniAb technology platform is a patent-protected transgenic animal
platform used in the discovery of fully human mono- and bispecific
therapeutic antibodies. The Captisol® platform technology is a
patent-protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs The
Vernalis Design Platform (VDP) integrates protein structure
determination and engineering, fragment screening and molecular
modeling, with medicinal chemistry, to help enable success in novel
drug discovery programs against highly-challenging targets. Ligand
has established multiple alliances, licenses and other business
relationships with the world’s leading pharmaceutical companies
including Amgen, Merck, Pfizer, Gilead, Janssen, Baxter
International and Eli Lilly. For more information, please visit
www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191112005473/en/
Ligand Pharmaceuticals Incorporated Patrick O’Brien
investors@ligand.com (858) 550-7768 @Ligand_LGND LHA Bruce Voss
bvoss@lhai.com (310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024